Clinical trial
Bortezomib in Treating Patients With Myelodysplastic Syndromes
NCT00262873 · University of Rochester, Other · Completed
Key facts
| NCT number | NCT00262873 |
|---|---|
| Title | Bortezomib in Treating Patients With Myelodysplastic Syndromes |
| Official title | A Phase II Pilot Study of VELCADE in Patients With MDS |
| Lead sponsor | University of Rochester, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 8 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Dec 7, 2005 |
| Last update posted | May 9, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: